Residency · Residency · Pediatrics
Type 1 Diabetes: Diagnosis, DKA, and Ongoing Management
Introduction
Type 1 diabetes mellitus (T1DM) is an autoimmune disease resulting in progressive destruction of pancreatic beta cells, leading to absolute insulin deficiency. It is the most common form of diabetes in children, with a peak incidence between ages 5-7 and again at puberty. Approximately 30-50% of newly diagnosed children present in diabetic ketoacidosis (DKA), a life-threatening metabolic emergency that demands rapid recognition and careful management.
Pathophysiology
Autoimmune destruction of beta cells is mediated by T-lymphocytes in genetically susceptible individuals, with strong HLA DR3/DR4 associations. Environmental triggers may include viral infections (enterovirus, coxsackievirus), dietary factors, and gut microbiome alterations. Autoantibodies serve as biomarkers of the disease process and include GAD65, IA-2, insulin autoantibodies (IAA), and ZnT8. Clinical diabetes manifests when approximately 80-90% of beta-cell mass has been destroyed. The "honeymoon period" occurs in some patients after diagnosis, representing partial beta-cell recovery with reduced insulin requirements lasting weeks to months.
Diagnosis
Clinical Presentation
The classic triad is polyuria, polydipsia, and weight loss. Additional symptoms include fatigue, blurred vision, candidal infections, and nocturnal enuresis in previously continent children. DKA presents with nausea and vomiting, abdominal pain, Kussmaul respirations, fruity breath odor, and altered mental status.
Diagnostic Criteria
Diagnosis is established by a fasting plasma glucose of 126 mg/dL or greater, a random plasma glucose of 200 mg/dL or greater with symptoms, an HbA1c of 6.5% or greater, or a 2-hour oral glucose tolerance test value of 200 mg/dL or greater (though OGTT is rarely used in pediatrics when symptoms are present). Confirmation with an autoantibody panel and C-peptide level (low or undetectable in T1DM) is important.
<image>Diagram illustrating autoimmune pathogenesis of Type 1 diabetes, showing T-cell mediated beta-cell destruction in pancreatic islets with associated autoantibodies labeled</image>
Diabetic Ketoacidosis (DKA) Management
Classification of DKA Severity
| DKA Severity | pH | Bicarbonate (mEq/L) |
|---|---|---|
| Mild | 7.20-7.30 | 10-15 |
| Moderate | 7.10-7.19 | 5-9 |
| Severe | <7.10 | <5 |
Mild DKA is defined by a pH of 7.20-7.30 and bicarbonate of 10-15 mEq/L. Moderate DKA has a pH of 7.10-7.19 and bicarbonate of 5-9 mEq/L. Severe DKA has a pH below 7.10 and bicarbonate below 5 mEq/L.
Acute Management Protocol
Fluid resuscitation begins with an initial normal saline bolus of 10-20 mL/kg over 1-2 hours. Overly aggressive rehydration must be avoided due to the risk of cerebral edema. An insulin infusion of regular insulin at 0.05-0.1 units/kg/hr is started after the initial fluid bolus; insulin should not be given as a bolus. Potassium replacement begins once potassium is below 5.5 mEq/L and urine output is confirmed, using a combination of KCl and KPhos. Blood glucose is monitored hourly, and dextrose is added to the IV fluids when glucose falls below 250-300 mg/dL to prevent hypoglycemia while continuing insulin to clear ketones. Bicarbonate is generally not recommended and should be considered only if the pH is below 6.9 with hemodynamic instability.
Cerebral Edema -- The Most Feared Complication
Cerebral edema occurs in 0.5-1% of pediatric DKA episodes and carries a mortality rate of 20-25%. Risk factors include younger age, new-onset diabetes, severe acidosis, excessive fluid administration, and rapid glucose decline. Signs include headache, altered mental status, bradycardia, hypertension, and pupillary changes. Treatment is hypertonic saline (3%) at 5-10 mL/kg or mannitol at 0.5-1 g/kg IV, with head of bed elevation and reduction in IV fluid rate.
<image>Flowchart of DKA management protocol in pediatrics showing stepwise approach from initial assessment through fluid resuscitation, insulin therapy, electrolyte monitoring, and transition to subcutaneous insulin</image>
Ongoing Management
Insulin Regimens
Basal-bolus therapy uses a long-acting insulin (glargine or detemir) plus rapid-acting insulin (lispro, aspart) at meals. Insulin pump therapy (CSII) provides continuous subcutaneous insulin infusion and is increasingly used in pediatrics. Automated insulin delivery (AID) systems are hybrid closed-loop systems that integrate continuous glucose monitoring with an insulin pump.
Monitoring
Continuous glucose monitoring (CGM) is the standard of care, with a target Time in Range (70-180 mg/dL) of greater than 70%. The HbA1c target is below 7% for most children and adolescents per ISPAD and ADA guidelines. Screening for thyroid disease (TSH annually) and celiac disease (tTG-IgA at diagnosis and periodically) is recommended. Annual screening for microalbuminuria, lipid panel, and retinal exams begins 5 years after diagnosis or at puberty.
Nutrition and Education
Carbohydrate counting is essential for accurate mealtime insulin dosing. Insulin-to-carbohydrate ratios and correction factors are individualized per patient. Exercise management requires reducing basal insulin or consuming extra carbohydrates to prevent hypoglycemia.
<image>Illustration comparing normal glucose regulation vs Type 1 diabetes showing insulin secretion patterns, blood glucose levels across a 24-hour period, and the concept of basal-bolus insulin replacement</image>
Clinical Pearls
DKA should always be checked for at diagnosis because even a well-appearing child may have significant acidosis. Cerebral edema in DKA is a clinical diagnosis, and treatment should not be delayed for imaging. The "honeymoon phase" does not mean the diabetes has resolved, and close follow-up and education must be maintained. Sick-day management is critical: basal insulin must never be stopped, ketones should be checked frequently, and hydration must be maintained. Mental health screening should be integrated into routine diabetes care because rates of depression, anxiety, and disordered eating are elevated in youth with T1DM.
References
- American Diabetes Association. Standards of Medical Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1).
- Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic Ketoacidosis and the Hyperglycemic Hyperosmolar State. Pediatric Diabetes. 2018;19(Suppl 27):155-177.
- Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009. JAMA. 2014;311(17):1778-1786.
- Steck AK, Rewers MJ. Genetics of Type 1 Diabetes. Clinical Chemistry. 2011;57(2):176-185.
